These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2578313)

  • 1. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer.
    Killian CS; Yang N; Emrich LJ; Vargas FP; Kuriyama M; Wang MC; Slack NH; Papsidero LD; Murphy GP; Chu TM
    Cancer Res; 1985 Feb; 45(2):886-91. PubMed ID: 2578313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer.
    Killian CS; Emrich LJ; Vargas FP; Yang N; Wang MC; Priore RL; Murphy GP; Chu TM
    J Natl Cancer Inst; 1986 Feb; 76(2):179-85. PubMed ID: 2418245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of human prostate-specific antigen in monitoring prostate cancer.
    Kuriyama M; Wang MC; Lee CI; Papsidero LD; Killian CS; Inaji H; Slack NH; Nishiura T; Murphy GP; Chu TM
    Cancer Res; 1981 Oct; 41(10):3874-6. PubMed ID: 7284995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
    Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
    J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
    Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
    Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
    Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of prostate antigen (PA) in prostate cancer].
    Kuriyama M
    Gan No Rinsho; 1985 May; 31(6 Suppl):606-10. PubMed ID: 2411962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
    Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
    J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer.
    Ramos CG; Roehl KA; Antenor JA; Humphrey PA; Catalona WJ
    J Urol; 2004 Jul; 172(1):137-40. PubMed ID: 15201754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer.
    Ricciardelli C; Mayne K; Sykes PJ; Raymond WA; McCaul K; Marshall VR; Tilley WD; Skinner JM; Horsfall DJ
    Clin Cancer Res; 1997 Jun; 3(6):983-92. PubMed ID: 9815775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Carl S. Killian et al. Prognostic importance of prostate-specific antigen for monitoring patients with stage B2 to D1 prostate cancer.
    Bartkus JM; Ablin RJ
    Cancer Res; 1985 Nov; 45(11 Pt 2):5984-5. PubMed ID: 2414005
    [No Abstract]   [Full Text] [Related]  

  • 19. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
    Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
    J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.